CIC-rearranged sarcoma is a rare, aggressive soft tissue cancer defined by a CIC gene fusion, usually with DUX4. It mainly affects young adults, often spreads to the lungs and is treated with surgery, radiotherapy and intensive chemotherapy.
What is CIC-rearranged sarcoma?
CIC-rearranged sarcoma is a very rare, aggressive cancer of the soft tissues. It is defined by a specific change in the tumour’s genes: part of the CIC gene on chromosome 19 becomes joined to another gene, most often DUX4. This joining, called a gene fusion, switches on growth signals that drive the cancer. When the partner is DUX4, the tumour is also called CIC::DUX4 sarcoma.
Under the microscope, the tumour is made of small, round blue cells, so it was long thought to be a type of Ewing sarcoma. Doctors used terms such as “Ewing-like sarcoma” or “atypical Ewing sarcoma”. Research then showed that these tumours look, behave and respond to treatment differently. They are now recognised as a separate disease (Antonescu et al., 2017) within a group called undifferentiated small round cell sarcomas.
CIC-rearranged sarcoma usually affects young adults, although children and older adults can also develop it. It typically forms a deep lump in the muscles of the trunk or limbs. It often spreads early, especially to the lungs, and has a poorer outlook than Ewing sarcoma (Makise and Yoshida, 2024).
Treatment combines surgery, radiotherapy and chemotherapy, usually in a specialist sarcoma centre. There is no agreed standard drug treatment, and clinical trials are encouraged (Brahmi et al., 2022).
1. Key facts at a glance
2. Types
In the large study by Antonescu and colleagues, a CIC::DUX4 fusion was found in 57% of 115 tumours. The rest had CIC rearrangements with partners that could not always be identified.
How it differs from Ewing sarcoma
The survival comparison comes from a study matching patients by age and stage (Antonescu et al., 2017).
3. Causes and risk factors
The cause of CIC-rearranged sarcoma is not known.
The fusion causes ETV4 and related genes to become overactive, driving uncontrolled cell growth (Brahmi et al., 2022). The fusion is present only in the cancer cells, so relatives are not at increased risk.
4. How does it look
Where it grows
On scans
Under the microscope
Confirming the fusion
Genetic tests can miss CIC::DUX4 fusions, even with modern sequencing. Pathologists therefore combine the appearance, the stains and several tests before making the diagnosis (Makise and Yoshida, 2024).
5. Symptoms
Common symptoms
- A lump or swelling, often deep in a muscle of the trunk, thigh or arm
- A lump that grows quickly over weeks
- Pain in the area, though some lumps are painless
Less common symptoms
When to seek medical advice
See a doctor about any lump that is larger than 5 cm, growing, deep or painful. Most lumps are harmless, but these features warrant an urgent scan and referral to a sarcoma service.
6. Diagnosis
Staging
Staging uses the TNM system for soft tissue sarcoma, considering size, depth, lymph node involvement and distant spread. Because CIC-rearranged sarcoma is a high-grade tumour, even localised disease is treated intensively.
In an Australian multi-centre series, 11 of 18 patients had localised disease and 7 had advanced disease at diagnosis (Connolly et al., 2022).
7. Treatment
There is no agreed standard treatment. Many centres use an Ewing sarcoma-style approach; others treat it like a high-grade soft tissue sarcoma. Experts recommend combinations of an anthracycline and an alkylating agent where possible, and advise against reducing treatment intensity (Brahmi et al., 2022).
Localised disease
In the Australian series, most patients with localised disease had complete surgical removal, and most also received radiotherapy and chemotherapy. Even so, more than half later developed metastases, usually within the first year (Connolly et al., 2022).
Chemotherapy regimens
Advanced disease
In the Australian series, responses to drug treatment in advanced disease rarely lasted. One patient had a durable complete response to VDC/IE, while single patients given pazopanib or pembrolizumab did not respond (Connolly et al., 2022).
A typical treatment plan for localised disease
Why specialist centres matter
Sarcomas are rare, and CIC-rearranged sarcoma is among the rarest. Specialist teams bring together sarcoma surgeons, oncologists, radiologists and pathologists experienced in molecular diagnosis. Such teams are better placed to confirm the diagnosis, plan surgery that preserves function, and offer access to clinical trials and registries, which experts strongly recommend for this disease (Brahmi et al., 2022).
Side effects
8. Outlook (prognosis)
CIC-rearranged sarcoma has a poor overall prognosis, worse than that of Ewing sarcoma (Makise and Yoshida, 2024).
Some patients do achieve long-term remission, particularly with localised disease treated in a specialist centre.
9. Follow-up
Late effects to monitor
10. Living with CIC-rearranged sarcoma
- Ask to be treated in a specialist sarcoma centre
- Discuss fertility preservation before chemotherapy
- Report fever promptly during chemotherapy
- Work with physiotherapists to keep movement and strength after surgery
- Ask about clinical trials at diagnosis and if the cancer returns
- Eat well and stay as active as you can during treatment, with advice from a dietitian if needed
- Seek emotional support; young adult cancer services and sarcoma charities can help
- Keep follow-up appointments, as early detection of lung spread can allow treatment
11. Frequently asked questions
12. Questions to ask your care team
- Has the CIC fusion been confirmed, and with which partner gene?
- Has the cancer spread?
- Which chemotherapy do you recommend, and why?
- Will I need surgery and radiotherapy?
- How can I protect my fertility?
- Are there clinical trials for this sarcoma?
- What follow-up will I need?
- Who should I contact if I develop a fever or new symptoms?
- What support is available for work, study and finances?
Resources
- Antonescu, C.R. et al. (2017) ‘Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases’, American Journal of Surgical Pathology, 41(7), pp. 941-949.
- Brahmi, M. et al. (2022) ‘CIC-DUX4 sarcomas’, Current Opinion in Oncology, 34(4), pp. 342-347.
- Connolly, E.A. et al. (2022) ‘Systemic treatments and outcomes in CIC-rearranged sarcoma: a national multi-centre clinicopathological series and literature review’, Cancer Medicine, 11(8), pp. 1805-1816.
- Makise, N. and Yoshida, A. (2024) ‘CIC-rearranged sarcoma’, Surgical Pathology Clinics, 17(1), pp. 141-151.
- National Cancer Institute (2026) Adult Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.